Skip to main content

BioSniper ranking

Nearest Upcoming Biotech Catalysts

Biotech catalysts — PDUFA decisions, AdCom meetings, clinical trial readouts, FDA approvals, and patent expirations — are the events that move small- and mid-cap biotech stocks. This ranking merges every catalyst type into a single list, nearest first, so you can see what is coming across the sector.

Ranked entities
100
Freshness
No verified data date available
Method
Published source data
BioSniper AIPage evidence connected

Prepared research question

Why is Phase1_Start: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With → INCY in this position, and what could change the ranking?

Run cited research

Traceable citations · Unknowns marked

  1. 1Phase1_Start: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic ImpairmentIncyte Corp. (INCY)Oct 13, 2026Phase1 Start
  2. 2Phase2_Start: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2a/b Study Assessing the Efficacy, Safety and Tolerability of DDY391 in Participants With Active Moderate to Severe Psoriatic ArthritisNovartis AG (NVS)Oct 14, 2026Phase2 Start
  3. 3Phase3_Start: Veterans' Intervention Blending NeuRomodulation and YogA for Chronic Low Back PaiN Treatment: VIBRANTGH Research PLC (GHRS)Oct 14, 2026Phase3 Start
  4. 4Phase3_Start: Safety and Efficacy of Ivarmacitinib Versus Glucocorticoids in Patients With Mild-to-Moderate Systemic Lupus Erythematosus: A Randomized, Double-Blind, Noninferiority Clinical TrialGH Research PLC (GHRS)Oct 15, 2026Phase3 Start
  5. 5Phase1_Start: A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic ImpairmentBeOne Medicines Ltd. (ONC)Oct 15, 2026Phase1 Start
  6. 6Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionViking Therapeutics, Inc. (VKTX)Oct 15, 2026Phase3 Start
  7. 7Phase1_Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid LeukemiaCullinan Therapeutics, Inc. (CGEM)Oct 15, 2026Phase1 Start
  8. 8Phase3_Start: A Phase 3, Single-Arm, Open-Label, Long-Term Extension Study To Evaluate The Safety And Efficacy Of Enpatoran In Participants With Active Cutaneous Manifestations Of Lupus Erythematosus With Or Without Systemic Disease Receiving Standard Of Care [Elowen-LTE]GH Research PLC (GHRS)Oct 15, 2026Phase3 Start
  9. 9Phase2_Start: Phase 2 Platform Trial of Combination Therapies for Participants With Locally Advanced Basal Cell Carcinoma: Master Protocol With Cemiplimab Monotherapy as Comparator ArmREGENERON PHARMACEUTICALS, INC. (REGN)Oct 15, 2026Phase2 Start
  10. 10Phase2_Start: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With SepsisImmunityBio, Inc. (IBRX)Oct 15, 2026Phase2 Start
  11. 11Phase2_Start: A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA NephropathyARGENX SE (ARGX)Oct 15, 2026Phase2 Start
  12. 12Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or OverweightViking Therapeutics, Inc. (VKTX)Oct 16, 2026Phase3 Start
  13. 13Phase1_Start: An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and Absolute Bioavailability of AZD4954 in Healthy Male ParticipantsASTRAZENECA PLC (AZN)Oct 19, 2026Phase1 Start
  14. 14Earnings: Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call DatesMolina Healthcare Inc (MOH)Oct 21, 2026Earnings
  15. 15Phase2_Start: A Randomized, Double-Blind, Placebo-Controlled MAD Study With Open-Label Extension to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BIIB147 Administered Intrathecally to Adult Participants With ALSBIOGEN INC. (BIIB)Oct 22, 2026Phase2 Start
  16. 16Phase1_Start: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic ImpairmentBeOne Medicines Ltd. (ONC)Oct 22, 2026Phase1 Start
  17. 17Earnings: Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026Quest Diagnostics Incorporated (DGX)Oct 22, 2026Earnings
  18. 18Phase3_Start: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial HypertensionInhibikase Therapeutics, Inc. (IKT)Oct 23, 2026Phase3 Start
  19. 19Phase2_Start: Phase 1/2 Open-Label Trial With Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants With Symptomatic Prion DiseaseREGENERON PHARMACEUTICALS, INC. (REGN)Oct 23, 2026Phase2 Start
  20. 20Phase2_Start: A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell CarcinomaFATE THERAPEUTICS INC (FATE)Oct 25, 2026Phase2 Start
  21. 21Phase1_Start: A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on HemodialysisIncyte Corp. (INCY)Oct 26, 2026Phase1 Start
  22. 22Phase2_Start: A Phase 2 Study of INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy (NEXERA-204)Incyte Corp. (INCY)Oct 26, 2026Phase2 Start
  23. 23Phase2_Start: A Phase 2a Randomized, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of LIQ861 in Participants With Systemic Sclerosis Experiencing Symptomatic Raynaud's Phenomenon Attacks / RE-WARMLiquidia Corp (LQDA)Oct 26, 2026Phase2 Start
  24. 24Phase3_Start: Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNovo Nordisk A/S (NVO)Oct 26, 2026Phase3 Start
  25. 25Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. (LRMR)Oct 26, 2026Phase3 Start
  26. 26Earnings: Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026Beta Bionics Inc. (BBNX)Oct 27, 2026Earnings
  27. 27Earnings: IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026IQVIA Holdings Inc. (IQV)Oct 27, 2026Earnings
  28. 28Phase2_Start: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy and Safety of JNJ-95597528 for the Treatment of Adult Participants With Inadequately Controlled Moderate to Severe AsthmaGH Research PLC (GHRS)Oct 29, 2026Phase2 Start
  29. 29Phase1_Start: A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy ParticipantsINSMED Inc (INSM)Oct 29, 2026Phase1 Start
  30. 30Earnings: AbbVie to Host Third-Quarter 2026 Earnings Conference CallAbbVie Inc. (ABBV)Oct 30, 2026Earnings
  31. 31Phase3_Start: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Cannabidiol Oral Solution (CBD-OS, JZP926-OS) in Participants Aged 1 Year and Older With Developmental and Epileptic Encephalopathy (DEE)Jazz Pharmaceuticals plc (JAZZ)Oct 30, 2026Phase3 Start
  32. 32Phase2_Start: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive DisorderBRISTOL MYERS SQUIBB CO (BMY)Oct 30, 2026Phase2 Start
  33. 33Phase2_Start: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 52-Week Trial to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityREGENERON PHARMACEUTICALS, INC. (REGN)Oct 30, 2026Phase2 Start
  34. 34Phase1_Start: A First-in-human, Prospective Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of SZN-8141 in Diabetic Macular EdemaSurrozen Inc. (SRZN)Oct 30, 2026Phase1 Start
  35. 35Phase1_Start: A Multicentre, Randomised, Open-label, Phase I Study to Characterise the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Administered Subcutaneously or Intravenously in Participants With Systemic Lupus ErythematosusASTRAZENECA PLC (AZN)Oct 30, 2026Phase1 Start
  36. 36Phase1_Start: A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid TumorsRadiopharm Theranostics Limited (RADX)Oct 30, 2026Phase1 Start
  37. 37Phase2_Start: A Multicentre, Prospective, Randomized, Open-label, Blinded Endpoint, Pilot Clinical Trial Evaluating Subcutaneous Semaglutide in Patients With Acute Ischaemic Stroke Due to Anterior Circulation Large Vessel Occlusion Treated With Endovascular ThrombectomyGH Research PLC (GHRS)Oct 31, 2026Phase2 Start
  38. 38Phase2_Start: Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age With Immunoglobulin G4-related Disease (IgG4-RD)AMGEN INC (AMGN)Oct 31, 2026Phase2 Start
  39. 39Phase3_Start: A Phase 2/3, Double-blind, Randomized, Placebo-Controlled, Multicenter, Efficacy, Safety, and Pharmacokinetics Study of AG-236 in Subjects With Polycythemia VeraAGIOS PHARMACEUTICALS, INC. (AGIO)Nov 1, 2026Phase3 Start
  40. 40Phase2_Start: EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)UNITED THERAPEUTICS Corp (UTHR)Nov 1, 2026Phase2 Start
  41. 41Phase3_Start: A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) DiseasePolaryx Therapeutics Inc. (PLYX)Nov 1, 2026Phase3 Start
  42. 42Phase2_Start: Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisUNITED THERAPEUTICS Corp (UTHR)Nov 1, 2026Phase2 Start
  43. 43Phase1_Start: A Phase 1, Double-blind, Placebo-Controlled, First-in-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses ofABBV-1162 in Healthy SubjectsAbbVie Inc. (ABBV)Nov 2, 2026Phase1 Start
  44. 44Earnings: Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2Axsome Therapeutics, Inc. (AXSM)Nov 2, 2026Earnings
  45. 45Phase1_Start: A Phase 1, Single-Ascending Dose Study of REGN24493, an Anti-TSHR Monoclonal Antibody, in Participants With Graves' DiseaseREGENERON PHARMACEUTICALS, INC. (REGN)Nov 2, 2026Phase1 Start
  46. 46Phase3_Start: Improving Pain and Functioning Using an Integrative Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving BuprenorphineGH Research PLC (GHRS)Nov 2, 2026Phase3 Start
  47. 47Earnings: Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results AnnouncementElanco Animal Health Inc (ELAN)Nov 6, 2026Earnings
  48. 48Phase3_Start: A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)REGENERON PHARMACEUTICALS, INC. (REGN)Nov 6, 2026Phase3 Start
  49. 49Earnings: Regulation FD Disclosure.: August 10, 2026, Elite Pharmaceuticals, Inc. ("Elite" or the "Company") issued a press release announcing thatELITE PHARMACEUTICALS INC /NV/ (ELTP)Nov 14, 2026Earnings
  50. 50PDUFA: ivonescimabSummit Therapeutics Inc. (SMMT)Nov 14, 2026PDUFA
  51. 51Phase3_Start: A Phase 3 Study With an Open-Label Extension in Pediatric Participants to Evaluate the Safety, Efficacy, and Pharmacokinetics of Diroximel Fumarate and Dimethyl Fumarate for the Treatment of Relapsing Forms of Multiple SclerosisBIOGEN INC. (BIIB)Nov 16, 2026Phase3 Start
  52. 52PDUFA: 0001104659-26-100071CAPRICOR THERAPEUTICS, INC. (CAPR)Nov 22, 2026PDUFA
  53. 53Phase2_Start: A Phase 1/2 Study of REGN13089-M404-M2980, a MET-targeting Antibody-Drug Conjugate in Adult Participants With Previously Treated Advanced Solid TumorsREGENERON PHARMACEUTICALS, INC. (REGN)Nov 23, 2026Phase2 Start
  54. 54Phase3_Start: A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisAbbVie Inc. (ABBV)Nov 29, 2026Phase3 Start
  55. 55Phase3_Start: A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)AbbVie Inc. (ABBV)Nov 30, 2026Phase3 Start
  56. 56Phase2_Start: A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and DurvalumabJazz Pharmaceuticals plc (JAZZ)Nov 30, 2026Phase2 Start
  57. 57Phase3_Start: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesELI LILLY & Co (LLY)Dec 1, 2026Phase3 Start
  58. 58Phase3_Start: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase InhibitorCellectar Biosciences, Inc. (CLRB)Dec 1, 2026Phase3 Start
  59. 59Phase2_Start: A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal HyperplasiaNEUROCRINE BIOSCIENCES INC (NBIX)Dec 1, 2026Phase2 Start
  60. 60Phase2_Start: The Use of Tranexamic Acid in Decreasing Wound Complication in Total Ankle Replacement. A Pilot Randomized Controlled TrialGH Research PLC (GHRS)Dec 1, 2026Phase2 Start
  61. 61Phase2_Start: A Phase Ib/II Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerGH Research PLC (GHRS)Dec 1, 2026Phase2 Start
  62. 62Phase1_Start: Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial CarcinomaImmunityBio, Inc. (IBRX)Dec 1, 2026Phase1 Start
  63. 63Phase1_Start: An Open-Label Phase Ib, Multicenter Study To Evaluate The Safety And Efficacy Of Belantamab Mafodotin Plus Cevostamab And Pomalidomide In Participants With Relapsed/Refractory Multiple Myeloma (RRMM)GH Research PLC (GHRS)Dec 1, 2026Phase1 Start
  64. 64Phase2_Start: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré SyndromeARGENX SE (ARGX)Dec 1, 2026Phase2 Start
  65. 65Phase3_Start: A Phase 3, Double-Blind, Randomized, Controlled Study of INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1 (MAESTRA 3)Incyte Corp. (INCY)Dec 1, 2026Phase3 Start
  66. 66Phase3_Start: A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel Group Study of Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Progressive Pulmonary Fibrosis (PPF)-PALM-PPFINSMED Inc (INSM)Dec 1, 2026Phase3 Start
  67. 67Phase3_Start: A Phase 3, Randomized, Single-blind, Parallel Group, Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebroventricular Tralesinidase Alfa Treatment Compared to Standard of Care in Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)SPRUCE BIOSCIENCES, INC. (SPRB)Dec 1, 2026Phase3 Start
  68. 68Phase3_Start: PH Weighted Chemical Exchange Saturation Transfer Based Surgical Resections of GlioblastomaBlack Diamond Therapeutics, Inc. (BDTX)Dec 1, 2026Phase3 Start
  69. 69Phase2_Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refractory Immune Thrombocytopenia and Warm Autoimmune Hemolytic AnemiaCullinan Therapeutics, Inc. (CGEM)Dec 1, 2026Phase2 Start
  70. 70Phase1_Start: A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic StenosisGH Research PLC (GHRS)Dec 1, 2026Phase1 Start
  71. 71Phase1_Start: A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated GlioblastomaGH Research PLC (GHRS)Dec 1, 2026Phase1 Start
  72. 72Phase2_Start: A Pilot Study, Open-Label Study of ONC201 for Refractory MeningiomaJazz Pharmaceuticals plc (JAZZ)Dec 1, 2026Phase2 Start
  73. 73Phase2_Start: An Open-Label, Multicenter, Phase 2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients With Lysosomal Storage Disorders (SOTERIA)Polaryx Therapeutics Inc. (PLYX)Dec 1, 2026Phase2 Start
  74. 74Phase2_Start: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's DiseaseIMPACT BIOMEDICAL INC. (IBO)Dec 1, 2026Phase2 Start
  75. 75Phase1_Start: A Phase 1, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative ColitisAttovia Therapeutics, Inc. (ATTO)Dec 14, 2026Phase1 Start
  76. 76Phase2_Start: A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung CancerEXELIXIS, INC. (EXEL)Dec 15, 2026Phase2 Start
  77. 77Phase2_Start: An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.Novartis AG (NVS)Dec 15, 2026Phase2 Start
  78. 78Phase2_Start: A Phase 2, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy (FIGHT-214)Incyte Corp. (INCY)Dec 15, 2026Phase2 Start
  79. 79Phase3_Start: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisBRISTOL MYERS SQUIBB CO (BMY)Dec 16, 2026Phase3 Start
  80. 80Phase2_Start: A Phase II Randomized Study of Reirradiation for Locally Recurrent Non-Small Cell Lung CancerCG Oncology, Inc. (CGON)Dec 18, 2026Phase2 Start
  81. 81Phase2_Start: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ATTO-1310 for the Treatment of Participants With Chronic Pruritus of Unknown OriginAttovia Therapeutics, Inc. (ATTO)Dec 21, 2026Phase2 Start
  82. 82PDUFA: lorundrostatMineralys Therapeutics, Inc. (MLYS)Dec 22, 2026PDUFA
  83. 83PDUFA: relutriginePraxis Precision Medicines, Inc. (PRAX)Dec 27, 2026PDUFA
  84. 84Phase2_Topline: Regulation FD Disclosure.: On May 27, 2026, Apogee Therapeutics, Inc. (the "Company")Apogee Therapeutics, Inc. (APGE)Dec 31, 2026Phase2 Topline
  85. 85Phase2_Topline: IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosureIGC Pharma, Inc. (IGC)Dec 31, 2026Phase2 Topline
  86. 86Phase2_Start: A Phase IIb Study of the Safety and Efficacy of Nabiximols in Subjects With Spasticity Due to Neuromyelitis Optica Spectrum Disorders: A Double-blind, Randomized, Placebo-Controlled, Crossover StudyJazz Pharmaceuticals plc (JAZZ)Dec 31, 2026Phase2 Start
  87. 87Phase2_Topline: Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business UpdateTvardi Therapeutics, Inc. (TVRD)Dec 31, 2026Phase2 Topline
  88. 88Phase2_Topline: Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business UpdateTvardi Therapeutics, Inc. (TVRD)Dec 31, 2026Phase2 Topline
  89. 89Phase2_Topline: Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateZenas BioPharma, Inc. (ZBIO)Dec 31, 2026Phase2 Topline
  90. 90Phase2_Start: The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)Curative Biotechnology Inc (CUBT)Dec 31, 2026Phase2 Start
  91. 91Phase2_Start: Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)Curative Biotechnology Inc (CUBT)Dec 31, 2026Phase2 Start
  92. 92Phase2_Topline: 0001193125-26-281817Kymera Therapeutics, Inc. (KYMR)Dec 31, 2026Phase2 Topline
  93. 93Phase3_Start: A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent StudiesBRISTOL MYERS SQUIBB CO (BMY)Dec 31, 2026Phase3 Start
  94. 94Phase3_Start: A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-drug Conjugate (ADC) in Combination With a Checkpoint Inhibitor Compared to Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung CancerZai Lab Ltd (ZLAB)Dec 31, 2026Phase3 Start
  95. 95Phase2_Topline: Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions UnderwayClimb Bio, Inc. (CLYM)Dec 31, 2026Phase2 Topline
  96. 96Phase1_Start: Pilot and Feasibility Study of Intra-articular Anti-CD14 for the Treatment of Knee OsteoarthritisGH Research PLC (GHRS)Jan 1, 2027Phase1 Start
  97. 97Phase2_Start: A Phase Ib/Phase II Trial With Capivasertib Plus Immunotherapy in Bladder CancerGH Research PLC (GHRS)Jan 1, 2027Phase2 Start
  98. 98Patent_Expiry: NDA022110CUMBERLAND PHARMACEUTICALS INC (CPIX)Jan 1, 2027Patent Expiry
  99. 99Phase3_Start: A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined CutoffAbbVie Inc. (ABBV)Jan 6, 2027Phase3 Start
  100. 100Phase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)Novo Nordisk A/S (NVO)Jan 7, 2027Phase3 Start

Ranked by soonest date. Only dates confirmed in a primary source (SEC filing, FDA source, or company disclosure) are shown; speculative far-future dates are excluded.

Frequently asked questions

What counts as a biotech catalyst?

A catalyst is a scheduled or expected event that can materially move a stock — most commonly PDUFA dates, AdCom meetings, Phase 2/3 trial readouts, FDA approvals, and patent expirations.

How are catalyst dates verified?

BioSniper only shows a date when it appears in a primary source (SEC filing, FDA source, or company disclosure); speculative far-future dates are excluded.

How current is this ranking?

Event dates and source records are shown with their available source context.

From ranked signal to decision rule

Decide how this ranking should affect your thesis

Turn the ranking field into a criterion, add your own thresholds, and require supporting company evidence before it influences a decision.

Turn this signal into a thesis rule — freeTurn this signal into a thesis rule